drugset / Trial / NCT07215585
AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to measure the efficacy and safety of R-mini-CHOP × 2 followed by AZD0486 compared with R-mini-CHOP × 6 in elderly or unfit participants newly diagnosed with LBCL.
Timeline
- Start
- 2025-11-11
- Primary completion
- 2030-06-10
- Completion
- 2033-07-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclophosphamide | Other / unclassified | 400 mg/m2 | Intravenous |
| Subject | Doxorubicin | Other / unclassified | 25 mg/m2 | Intravenous |
| Subject | Prednisone | Other / unclassified | 40 mg/m2 | Oral |
| Subject | Rituximab | Monoclonal antibody | 375 mg/m2 | Intravenous |
| Subject | Surovatamig | Protein / enzyme biologic | — | — |
| Subject | Vincristine | Small molecule | 1 mg | Intravenous |